The one year survival rate of lung adenocarcinoma patients treated with chemotherapy or targeted therapy

Abstract

Background

Adenocarcinoma is the most common of lung Cancer. The treatment for early stage of lung Adenocarcinoma (I, II) is surgery. Targeted therapy is given to lung Adenocarcinoma patients with EGFR-TKI mutations. Chemotherapy is given to lung Adenocarcinoma patients without EGFR-TKI mutations.

Objective

To compare one-year survival of lung Adenocarcinoma patients treated with chemotherapy or targeted therapy.

Methods

This was a prospective study. The subjects were 100 patients with lung Adenocarcinoma.

Results

1-year Survival of lung Adenocarcinoma patient for one year was 18%. 1-year survival in patients with targeted therapy was higher than chemotherapy, which was 24% vs 9% (p < 0.01). 1-Year survival in chemotherapy patients with Carboplatin combined with Vinorelbin was higher than in other chemotherapy drugs (p > 0.05). 1-Year survival in patients with Erlotinib drug was 45% highest survival rate compared to chemotherapy drugs and other targeted therapy (p < 0.05). Patients receiving Erlotinib (45%) has the highest survival compared to all types of therapy.

Conclusion

Lung Adenocarcinoma patients receiving Erlotinib significantly had the highest survival rate compared to all other targeted therapy drugs and all types of chemotherapy drugs.